A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

Zepbound is a medicine you can obtain only by prescription, and it's typically used to address obesity and other ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) mechanisms to tackle the root causes of obesity.

Weight-loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are generating billions of dollars in sales Pharma rival Novo Nordisk (NYSE:NVO) was the first to market with its GLP-1 ...

Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...

are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to make it the S&P 500 index's SPX worst performer.

"FDA is aware that some patients and health care professionals may look to unapproved versions ... windy day': Live updates GLP-1 class drugs like Zepbound and Mounjaro form part of a larger ...